This Page Is Inserted by IFW Operations and is not a part of the Official Record

BEST AVAILABLE IMAGES


Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents will not correct images, please do not report the images to the Image Problem Mailbox.



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Goudsmit et al.

Application Serial No: 09/463,352

Group Art Unit: 1655 Examiner: B. Sisson

Filed: January 21, 2000

NUCLEIC ACID SEQUENCES THAT CAN BE USED AS PRIMERS AND PROBES IN

THE AMPLICATION AND DETECTION OF ALL SUBTYPES OF HIV-1

MAIL STOP RCE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

DECLARATION OF JAAP GOUDSMIT, PIETER OUDSHOORN, SUZANNE JURRIAANS AND VLADIMIR VLADIMIROVICH LUKASHOV UNDER 37 C.F.R. § 1.131

Sir:

For:

We, Jaap Goudsmit, Pieter Oudshoom, Suzanne Jurriaans and Vladimir Vladimirovich Lukashov hereby declare that:


- 1. We are the inventors of the subject matter of the rejected claims pending in the above-referenced patent application.
- 2. Prior to June 25, 1997, we conceived and reduced to practice the oligonucleotides having the nucleotide sequence of SEQ ID NOs 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 and 11, respectively, as recited in the pending claims, as well as methods of use and kits employing these oligonucleotides to detect HIV-1 nucleic acid in a sample
- 3. In support of the above statement, we hereby submit as Appendix A a copy of relevant pages of an internal memorandum entitled "Feasability of a qualitative NASBA assay with a broad HIV-1 clade reactivity" prepared by non-inventor, F. Jacobs, under the direction of

group leader and inventor, Pieter Oudshoom, and submitted to Akzo Nobel. The dates within this document have been blocked out, but are before June 25, 1997.

Specifically, this memorandum shows, in relevant part, with irrelevant text blocked out, on page 4 under section 2.1 entitled "Design of primers and probes," a listing of oligonucleotides identified as P1.1, P1.2, U5 end, P2.1, P2.2, HIV-1 LTR-bio, HIV-LTR-AMN1 and HIV-LTR-AMN2. These oligonucleotides are the oligonucleotides identified in the specification and pending claims as SEQ ID NO:1 and SEQ ID NO:9, SEQ ID NO:2 and SEQ ID NO:10, SEQ ID NO:3 and SEQ ID NO:12, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7 and SEQ ID NO:8, respectively. The oligonucleotides identified as SEQ ID NOs.1, 2 and 3 are the same as the oligonucleotides identified as SEQ ID NOs.9, 10 and 11, respectively, with the distinction that the latter three oligonucleotides are operably linked to a promoter sequence. (See page 7, lines 13-15 of the specification: "SEQ ID NO 9-11 actually comprise the sequence as reflected by SEQ ID 1-3. In SEQ ID 9-11, the sequences of SEQ ID 1-3 are operably linked to a promoter sequence (the T7 promoter sequence). This makes the sequences especially suitable for use as upstream primer in a transcription based amplification technique such as NASBA.")

The memorandum also shows, in relevant part, with irrelevant text blocked out, on page 5 under section 2.2, entitled "Evaluation and optimization of the primers and probes," a description of a protocol for detecting HIV nucleic acid using the oligonucleotides of this invention. Results obtained by conducting this protocol are shown, in relevant part, with irrelevant text blocked out, on page 10, under section 3.2, entitled "Evaluation of selected primers."

Jaap Goudsmit	Date	
PM_	Oct 15	+ 2003
Rigtor Oudshoom	Date	
Suzanne Jurriaans	Date	
Vladimir Vladimirovich Lukash	ov Date	*



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Goudsmit et al.

Application Serial No: 09/463,352

Group Art Unit: 1655

Filed: January 21, 2000

Examiner: B. Sisson

For:

NUCLEIC ACID SEQUENCES THAT CAN BE USED AS PRIMERS AND PROBES IN

THE AMPLICATION AND DETECTION OF ALL SUBTYPES OF HIV-1

MAIL STOP RCE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

DECLARATION OF JAAP GOUDSMIT, PIETER OUDSHOORN, SUZANNE JURRIAANS AND VLADIMIR VLADIMIROVICH LUKASHOV UNDER 37 C.F.R. § 1.131

Sir:

We, Jaap Goudsmit, Pieter Oudshoorn, Suzanne Jurriaans and Vladimir Vladimirovich Lukashov hereby declare that:


- We are the inventors of the subject matter of the rejected claims pending in the above-referenced patent application.
- Prior to June 25, 1997, we conceived and reduced to practice the oligonucleotides having the nucleotide sequence of SEQ ID NOs 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 and 11, respectively, as recited in the pending claims, as well as methods of use and kits employing these oligonucleotides to detect HIV-1 nucleic acid in a sample
- In support of the above statement, we hereby submit as Appendix A a copy of 3. relevant pages of an internal memorandum entitled "Feasability of a qualitative NASBA assay with a broad HIV-1 clade reactivity" prepared by non-inventor, F. Jacobs, under the direction of

group leader and inventor, Pieter Oudshoom, and submitted to Akzo Nobel. The dates within this document have been blocked out, but are before June 25, 1997.

Specifically, this memorandum shows, in relevant part, with irrelevant text blocked out, on page 4 under section 2.1 entitled "Design of primers and probes," a listing of oligonucleotides identified as P1.1, P1.2, U5 end, P2.1, P2.2, HIV-1 LTR-bio, HIV-LTR-AMN1 and HIV-LTR-AMN2. These oligonucleotides are the oligonucleotides identified in the specification and pending claims as SEQ ID NO:1 and SEQ ID NO:9, SEQ ID NO:2 and SEQ ID NO:10, SEQ ID NO: 3 and SEQ ID NO:12, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7 and SEQ ID NO:8, respectively. The oligonucleotides identified as SEQ ID NOs 1, 2 and 3 are the same as the oligonucleotides identified as SEQ ID NOs 9, 10 and 11, respectively, with the distinction that the latter three oligonucleotides are operably linked to a promoter sequence. (See page 7, lines 13-15 of the specification: "SEQ ID NO 9-11 actually comprise the sequence as reflected by SEQ ID 1-3. In SEQ ID 9-11, the sequences of SEQ ID 1-3 are operably linked to a promoter sequence (the T7 promoter sequence). This makes the sequences especially suitable for use as upstream primer in a transcription based amplification technique such as NASBA.")

The memorandum also shows, in relevant part, with irrelevant text blocked out, on page 5 under section 2.2, entitled "Evaluation and optimization of the primers and probes," a description of a protocol for detecting HIV nucleic acid using the oligonucleotides of this invention. Results obtained by conducting this protocol are shown, in relevant part, with irrelevant text blocked out, on page 10, under section 3.2, entitled "Evaluation of selected primers."

Jaap Goudsmit	Date
Pieter Oudshoom	Date
JW 3	30 Oct 2003
Suzanne Juriaans	Date
Vladimir Vladimirovich Lukashov	Date



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Goudsmit et al.

Application Serial No: 09/463,352

Group Art Unit: 1655

Filed: January 21, 2000

Examiner: B. Sisson

NUCLEIC ACID SEQUENCES THAT CAN BE USED AS PRIMERS AND PROBES IN

THE AMPLICATION AND DETECTION OF ALL SUBTYPES OF HIV-1

MAIL STOP RCE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

DECLARATION OF JAAP GOUDSMIT, PIETER OUDSHOORN, SUZANNE JURRIAANS AND VLADIMIR VLADIMIROVICH LUKASHOV UNDER 37 C.F.R. § 1.131

Sir:

We, Jaap Goudsmit, Pieter Oudshoom, Suzanne Jurriaans and Vladimir Vladimirovich Lukashov hereby declare that:


- We are the inventors of the subject matter of the rejected claims pending in the above-referenced patent application.
- Prior to June 25, 1997, we conceived and reduced to practice the oligonucleotides having the nucleotide sequence of SEQ ID NOs 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 and 11, respectively, as recited in the pending claims, as well as methods of use and kits employing these oligonucleotides to detect HIV-1 nucleic acid in a sample
- In support of the above statement, we hereby submit as Appendix A a copy of relevant pages of an internal memorandum entitled "Feasability of a qualitative NASBA assay with a broad HIV-1 clade reactivity" prepared by non-inventor, F. Jacobs, under the direction of

group leader and inventor, Pieter Oudshoom, and submitted to Akzo Nobel. The dates within this document have been blocked out, but are before June 25, 1997.

Specifically, this memorandum shows, in relevant part, with irrelevant text blocked out, on page 4 under section 2.1 entitled "Design of primers and probes," a listing of oligonucleotides identified as P1.1, P1.2, U5 end, P2.1, P2.2, HIV-1 LTR-bio, HIV-LTR-AMN1 and HIV-LTR-AMN2. These oligonucleotides are the oligonucleotides identified in the specification and pending claims as SEQ ID NO:1 and SEQ ID NO:9, SEQ ID NO:2 and SEQ ID NO:10, SEQ ID NO: 3 and SEQ ID NO:12, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7 and SEQ ID NO:8, respectively. The oligonucleotides identified as SEQ ID NOs 1, 2 and 3 are the same as the oligonucleotides identified as SEQ ID NOs 9, 10 and 11, respectively, with the distinction that the latter three oligonucleotides are operably linked to a promoter sequence. (See page 7, lines 13-15 of the specification: "SEQ ID NO 9-11 actually comprise the sequence as reflected by SEQ ID 1-3. In SEQ ID 9-11, the sequences of SEQ ID 1-3 are operably linked to a promoter sequence (the T7 promoter sequence). This makes the sequences especially suitable for use as upstream primer in a transcription based amplification technique such as NASBA.")

The memorandum also shows, in relevant part, with irrelevant text blocked out, on page 5 under section 2.2, entitled "Evaluation and optimization of the primers and probes," a description of a protocol for detecting HIV nucleic acid using the oligonucleotides of this invention. Results obtained by conducting this protocol are shown, in relevant part, with irrelevant text blocked out, on page 10, under section 3.2, entitled "Evaluation of selected primers."

•		
Jaap Goudsmit	Date	•
	Date	
Pieter Oudshoorn	Date	
Suzanne Jurriaans	Date Aktober 6 20	003
		ر_•
Vladimir Vladimirovich Lukashov	Dat e	• • • • •



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Goudsmit et al.

Application Serial No: 09/463,352

Group Art Unit: 1655 Examiner: B. Sisson Filed: January 21, 2000

For:

NUCLEIC ACID SEQUENCES THAT CAN BE USED AS PRIMERS AND PROBES IN

THE AMPLICATION AND DETECTION OF ALL SUBTYPES OF HIV-1

MAIL STOP RCE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

DECLARATION OF JAAP GOUDSMIT, PIETER OUDSHOORN, SUZANNE JURRIAANS AND VLADIMIR VLADIMIROVICH LUKASHOV UNDER 37 C.F.R. § 1.131

Sir:

We, Jaap Goudsmit, Pieter Oudshoorn, Suzanne Jurriaans and Vladimir Vladimirovich Lukashov hereby declare that:

- We are the inventors of the subject matter of the rejected claims pending in the above-referenced patent application.
- Prior to June 25, 1997, we conceived and reduced to practice the oligonucleotides having the nucleotide sequence of SEQ ID NOs 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 and 11, respectively, as recited in the pending claims, as well as methods of use and kits employing these oligonucleotides to detect HIV-1 nucleic acid in a sample
- In support of the above statement, we hereby submit as Appendix A a copy of 3. relevant pages of an internal memorandum entitled "Feasability of a qualitative NASBA assay with a broad HIV-1 clade reactivity" prepared by non-inventor, F. Jacobs, under the direction of

group leader and inventor, Pieter Oudshoom, and submitted to Akzo Nobel. The dates within this document have been blocked out, but are before June 25, 1997.

Specifically, this memorandum shows, in relevant part, with irrelevant text blocked out, on page 4 under section 2.1 entitled "Design of primers and probes," a listing of oligonucleotides identified as P1.1, P1.2, U5 end, P2.1, P2.2, HIV-1 LTR-bio, HIV-LTR-AMN1 and HIV-LTR-AMN2. These oligonucleotides are the oligonucleotides identified in the specification and pending claims as SEQ ID NO:1 and SEQ ID NO:9, SEQ ID NO:2 and SEQ ID NO:10, SEQ ID NO: 3 and SEQ ID NO:12, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7 and SEQ ID NO:8, respectively. The oligonucleotides identified as SEQ ID NOs 1, 2 and 3 are the same as the oligonucleotides identified as SEQ ID NOs 9, 10 and 11, respectively, with the distinction that the latter three oligonucleotides are operably linked to a promoter sequence. (See page 7, lines 13-15 of the specification: "SEQ ID NO 9-11 actually comprise the sequence as reflected by SEQ ID 1-3. In SEQ ID 9-11, the sequences of SEQ ID 1-3 are operably linked to a promoter sequence (the T7 promoter sequence). This makes the sequences especially suitable for use as upstream primer in a transcription based amplification technique such as NASBA.")

The memorandum also shows, in relevant part, with irrelevant text blocked out, on page 5 under section 2.2, entitled "Evaluation and optimization of the primers and probes," a description of a protocol for detecting HIV nucleic acid using the oligonucleotides of this invention. Results obtained by conducting this protocol are shown, in relevant part, with irrelevant text blocked out, on page 10, under section 3.2, entitled "Evaluation of selected primers."

Jaen Garimot	Ochdoen 3	3,2003
Jaap Goudsmit	Date	
Pieter Oudshoorn	Date	
Suzanne Jurriaans	Date	
Vladimir Vladimirovich Lukashov	Date	



Pharma Group

Confidential

SUBJMEMO

Organon Teknika by

R&D

Boxtel The Netherlands

Diagnostics

8747.970379

ntification: OMS nr.	8747.970379	Doc. Type:	REPORT	Proj. nr.: Rev. nr.:	423020 00
ekName: itle:	SUBJMEMO Feasibility of	Alt. nr.: a qualitative h	NASBA assay wit	n a broad HIV-1 cl	ade reactivity.
Part nrs.: Date created:	tin i	Supersedes	<u>.</u>	DAR/DCO:	1. N. 11. 2
Relevant DMRs:					
Keywords:			·	- 	
	_			Date:	Signature
ithor. Department:		Nam	e:		
NDU		F. J	acobs		
pproval:		Nan	ne:	Date:	Signature
Function: Groupleader		P. (Oudshoom		
Groupleader				***************************************	
		·			
			To be returned to	R&D secretary before	submitting for final app
Final authorization:		. Na	ате:	Date:	Signature
Function: NDU manager		C	. v. Buul		1
1 MDO Managor					

Mailing list

C.v. Eekelen, P.v.d. Wiel, P.Sillekens, B.Top, F. Roeles, R. Ehren, P.v. Aarle, C. de laat, E. Gobbers, R. van Erp*, J. Schalken*, E. Sprengers*, J. Leuvering*, A. Molenaar*, J.A. Hellings, R&D Doc. Services

Cover page of document.

*only frontpage + summary



narma Group

Confidential

SUBJMEMO

Organon Teknika bv

Boxtel The Netherlands

R&D

Diagnostics

8747.970379

- Materials and methods 2.
- Design of primers and probes. 2.1

. The oligonucleotide sequences are

respectively:

P1.1: aat tot aat acg act cac tat agg gAG AGG GGC GCC ACT GCT AGA GA

P1.2: aat tot aat acg act cac tat agg gAG AGG TTC GGG CGC CAC TGC TAG A

U5 end: aat tot aat acg act cac tat agg gCGGGCGCCACTGCTA

P2.1: CTG CTT AAA GCC TCA ATA AA

P2.2: CTC AAT AAA GCT TGC CTT GA

To perform ECL detection one biotin probe and two different detection probes were designed with the following sequences:

HIV-1 LTR-bio: TCT GGT AAC TAG AGA TCC CTC HIV-LTR-AMN1: TAG TGT GTG CCC GTC TGT. HIV-LTR-AMN2: AGT GTG TGC CCG TCT GTT.

		Authorized by:	Date:	Page:
Document nr.:	Revision:	Additionable by:		4 of 23
8747.970379	00	F. Jacobs		



Pharma Group

Confidential

SUBJMEMO

Organon Teknika by

Boxtel The Netherlands

Diagnostics

R&D

8747.970379

2.2 Evaluation and optimization of the primers and probes.

The primers were tested directly in the amplification in the combinations P1.1/P2.1, P1.1/P2.2, P1.2/P2.1, P1.2/P2.2 and U5-end/P2.2 on in vitro LTR RNA and on Scott Layne RNA (subtype B, stock solution of 5.5*109 copies RNA/ml). The input of the RNA was 10⁴ copies. The amplifications were examined on a 2% agarose gel and then blotted in 1 hour on zeta probe and cross-linked with UV. The blot was hybridized with the biotin probe (3 µM) by incubating the blot for 4 hours at 50°C. After hybridization the blot was washed two times for 5 minutes with 3*SSC/1%SDS solution at 50°C and one time for 10 minutes with 2*SSPE/0.1%SDS solution at RT. After this the blot was incubated for 30 minutes with 2 µl streptavidine/HRP solution (500 U/ml, Enhanced ChemiLuminiscense detection kit from Amersham) in 10 ml 5*SSPE/0.5%SDS. The blot was again washed two times for 5 minutes in 2*SSPE/0.1%SDS solution and one time for 10 minutes in 2*SSPE solution. The blot was dried between tissues and developed with the development solutions from the enhanced chemiluminiscense kit (Amersham). The blot was wrapped in Saran wrap and a film was placed on the blot for a couple of seconds. The film was developed according to the standard procedures.



Pharma Group

Confidenti^{*}

SUBJMEMO

Organon Teknika by

Boxtel The Netherlands

Diagnostics

8747.970379

Evaluation of selected primers. 3.2

Figure 3. Detection of the amplimers on blot.

The primersets used were: nr 1: P1.1-P2.1, nr 2: P1.1-P2.2, nr 3: P1.2-P2.1, nr 4: P1.2-P2.2, nr 5: U5 end-5'LTRSph1. The RNA used as input were: A: in vitro RNA 104 copies per input, B: Scott Layne RNA 104 copies per input, C: No Templates.

